Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Becton's simplified MSRA (methicillin-resistant Staphylococcus aureus) test:

This article was originally published in Clinica

Executive Summary

Becton Dickinson (BD) has received US FDA 510(k) clearance for a simplified test for detecting methicillin-resistant Staphylococcus aureus (MRSA). The BBL CHROMagar MRSA product consists of a prepared plated medium that allows patients colonised with the bacteria to be identified more quickly and easily than with the time-consuming and labour-intensive processes currently available, claimed the Baltimore, Maryland firm. It enables the direct detection and identification of most MRSA within 24 hours. The cost benefits associated with reducing nosocomial infections can be significant, the company added.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel